Abbott India Q1 FY26 – EPS ₹172, ROE 36%, P/E 44… Pharma Royalty or Just Branded Generic Show-off?
1. At a Glance
Abbott India struts around Dalal Street like the rich NRI cousin everyone pretends to like. With a market cap of ₹64,107 Cr and a current price of ₹30,168, it is one of the most expensive pharma scrips in town. Stock P/E is a princely 44.1—almost double the industry average of 34—because apparently vitamins taste better when priced like Louis Vuitton bags. Dividend yield? 1.59%—fancy enough to buy you one sugar-free muffin at Starbucks. Return on Equity? A jaw-dropping 35.7%. ROCE? 46.2%. Profit margins? A fat 22%. Basically, this is the corporate equivalent of that kid in school who scored 98/100, captained the cricket team, and also played tabla at annual day.
2. Introduction
Abbott India isn’t just another pharma company; it’s pharma royalty. Born in 1944 (yes, before India had Independence), the company has had more comebacks than Salman Khan. It’s part of Abbott Labs USA—a healthcare juggernaut spread across 160 countries with diagnostics, devices, nutrition, and pharma.
In India, Abbott plays the role of a branded generics powerhouse, selling pills with names that sound like the teacher’s nightmare in attendance class—Brufen, Thyrowel Plus, Arachitol Gummies. They even launched a Pneumococcal Conjugate Vaccine (PCV-14) last year—because why should babies cough when Abbott can bill?
Investors love to hate it. Pricey valuation? Check. Slow sales growth (9% CAGR in 5 years)? Check. Still, profit growth has been a steady 19% CAGR over five years. Like a shaadi buffet where dal tastes average but the jalebi is always piping hot.
But here’s the kicker: while peers are busy fighting in generics, Abbott India quietly dominates niches. Women’s health, gastro, CNS, metabolic disorders—they’ve got 125+ products. Some of their brands are literally ranked No.1 in India. Abbott doesn’t run in the generics rat race. It builds its own stadium.
3. Business Model – WTF Do They Even Do?
Abbott India’s business model is simple yet annoyingly effective:
Import parent company’s know-how,
Manufacture in Goa (14% of net sales),
Outsource rest to third-party contractors,
Distribute through 3,250 salespeople & stockists,
Convince doctors to scribble their brands on prescriptions,
Collect cash from chemists,
Smile.
Their portfolio is spread like a Diwali sweet platter:
Women’s health (contraceptives, menopause care)
Gastroenterology (acid reflux, IBS, indigestion—basically, the aam aadmi’s daily struggles)
Commentary: PAT flat QoQ, but YoY healthy. Margins remain royal at ~22%. Even when profits plateau, valuation stays sky-high. Abbott India trades like it has immunity from economic flu.
5. Valuation Discussion – Fair Value Range
a) P/E Method
EPS annualised = ₹688
Fair P/E range (given growth, ROE, global MNC tag): 35x–45x.
